These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 37337780)

  • 1. Metabolic-associated fatty liver disease in relation to site-specific and multiple-site subclinical atherosclerosis.
    Wang X; Zhang R; Man S; Lv J; Yu C; Yin J; Wang X; Deng Y; Wang B; Li L; Pang Y
    Liver Int; 2023 Aug; 43(8):1691-1698. PubMed ID: 37337780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A significant risk of metabolic dysfunction-associated fatty liver disease plus diabetes on subclinical atherosclerosis.
    Bessho R; Kashiwagi K; Ikura A; Yamataka K; Inaishi J; Takaishi H; Kanai T
    PLoS One; 2022; 17(5):e0269265. PubMed ID: 35639744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: A prospective analysis.
    Liu S; Wang J; Wu S; Niu J; Zheng R; Bie L; Xin Z; Wang S; Lin H; Zhao Z; Wang T; Xu M; Lu J; Chen Y; Xu Y; Wang W; Ning G; Bi Y; Li M; Xu Y
    Metabolism; 2021 Jul; 120():154779. PubMed ID: 33895182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations of subclinical atherosclerosis with nonalcoholic fatty liver disease and fibrosis assessed by non-invasive score.
    Xin Z; Zhu Y; Wang S; Liu S; Xu M; Wang T; Lu J; Chen Y; Zhao Z; Wang W; Ning G; Bi Y; Xu Y; Li M
    Liver Int; 2020 Apr; 40(4):806-814. PubMed ID: 31820847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of all-cause mortality associated with non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease in Taiwan MJ cohort.
    Cheng WC; Chen HF; Cheng HC; Li CY
    Epidemiol Health; 2024; 46():e2024024. PubMed ID: 38317531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between nonalcoholic fatty liver disease and subclinical atherosclerosis: a cross-sectional study on population over 40 years old.
    Zheng J; Zhou Y; Zhang K; Qi Y; An S; Wang S; Zhao X; Tang YD
    BMC Cardiovasc Disord; 2018 Jul; 18(1):147. PubMed ID: 30012085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic dysfunction-associated fatty liver disease increased the risk of subclinical carotid atherosclerosis in China.
    Lei F; Wang XM; Wang C; Huang X; Liu YM; Qin JJ; Zhang P; Ji YX; She ZG; Cai J; Li HP; Zhang XJ; Li H
    Front Endocrinol (Lausanne); 2023; 14():1109673. PubMed ID: 37082131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of diabetes on subclinical atherosclerosis and major cardiovascular events in individuals with and without non-alcoholic fatty liver disease.
    Wang B; Zhao Z; Liu S; Wang S; Chen Y; Xu Y; Xu M; Wang W; Ning G; Li M; Wang T; Bi Y
    Diabetes Res Clin Pract; 2021 Jul; 177():108873. PubMed ID: 34051282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonalcoholic Fatty Liver Disease Is Associated With Arterial Distensibility and Carotid Intima-Media Thickness: (from the Multi-Ethnic Study of Atherosclerosis).
    Oni E; Budoff MJ; Zeb I; Li D; Veledar E; Polak JF; Blankstein R; Wong ND; Blaha MJ; Agatston A; Blumenthal RS; Nasir K
    Am J Cardiol; 2019 Aug; 124(4):534-538. PubMed ID: 31262497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between non-alcoholic fatty liver disease and subclinical atherosclerosis in Western and Asian cohorts: an updated meta-analysis.
    Wong MYZ; Yap JJL; Sultana R; Cheah M; Goh GBB; Yeo KK
    Open Heart; 2021 Dec; 8(2):. PubMed ID: 34933963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of subclinical carotid artery atherosclerosis assessed by carotid ultrasound with nonalcoholic fatty liver disease fibrosis score in young and middle-aged men.
    Durak H; Çetin M; Emlek N; Özyıldız AG; Ergül E; Duman H
    Int J Cardiovasc Imaging; 2024 Sep; 40(9):1979-1986. PubMed ID: 39012403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic associated fatty liver disease better identifying patients at risk of liver and cardiovascular complications.
    Cheng YM; Wang CC; Kao JH
    Hepatol Int; 2023 Apr; 17(2):350-356. PubMed ID: 36471232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced fibrosis associates with atherosclerosis in subjects with nonalcoholic fatty liver disease.
    Chen Y; Xu M; Wang T; Sun J; Sun W; Xu B; Huang X; Xu Y; Lu J; Li X; Wang W; Bi Y; Ning G
    Atherosclerosis; 2015 Jul; 241(1):145-50. PubMed ID: 25988358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Associations of Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Fatty Liver Disease With Coronary Artery Calcification: A Cross-Sectional and Longitudinal Cohort Study.
    Sung KC; Yoo TK; Lee MY; Byrne CD; Zheng MH; Targher G
    Arterioscler Thromb Vasc Biol; 2023 Mar; 43(3):482-491. PubMed ID: 36727522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of concomitant hepatitis C virus infection on liver and cardiovascular risks in patients with metabolic-associated fatty liver disease.
    Tsai PS; Cheng YM; Wang CC; Kao JH
    Eur J Gastroenterol Hepatol; 2023 Nov; 35(11):1278-1283. PubMed ID: 37773778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency of Nonalcoholic Fatty Liver Disease and Subclinical Atherosclerosis Among Young Mexican Americans.
    Gill C; Vatcheva KP; Pan JJ; Smulevitz B; McPherson DD; Fallon M; McCormick JB; Fisher-Hoch SP; Laing ST
    Am J Cardiol; 2017 Jun; 119(11):1717-1722. PubMed ID: 28395890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of NAFLD with subclinical atherosclerosis and coronary-artery disease: meta-analysis.
    Ampuero J; Gallego-Durán R; Romero-Gómez M
    Rev Esp Enferm Dig; 2015 Jan; 107(1):10-6. PubMed ID: 25603326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver fibrosis is associated with carotid atherosclerosis in patients with liver biopsy-proven nonalcoholic fatty liver disease.
    Arai T; Atsukawa M; Tsubota A; Kato K; Abe H; Ono H; Kawano T; Yoshida Y; Tanabe T; Okubo T; Hayama K; Nakagawa-Iwashita A; Itokawa N; Kondo C; Kaneko K; Emoto N; Nagao M; Inagaki K; Fukuda I; Sugihara H; Iwakiri K
    Sci Rep; 2021 Aug; 11(1):15938. PubMed ID: 34354193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and clinical outcomes in subtypes of metabolic associated fatty liver disease.
    Cheng KL; Wang SW; Cheng YM; Hsieh TH; Wang CC; Kao JH
    J Formos Med Assoc; 2024 Jan; 123(1):36-44. PubMed ID: 37491179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between non-alcoholic fatty liver disease and subclinical coronary atherosclerosis: An observational cohort study.
    Lee SB; Park GM; Lee JY; Lee BU; Park JH; Kim BG; Jung SW; Jeong ID; Bang SJ; Shin JW; Park NH; Yang DH; Kang JW; Lim TH; Kim HK; Choe J; Lee HC
    J Hepatol; 2018 May; 68(5):1018-1024. PubMed ID: 29274406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.